Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05128201
Other study ID # NPC-CR01
Secondary ID 2020-PT320-004
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 1, 2021
Est. completion date May 31, 2026

Study information

Verified date February 2023
Source Jiangxi Provincial Cancer Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to explore the efficacy and tolerance of local consolidative radiotherapy combined with Camrelizumab and chemotherapy in patients with oligometastatic nasopharyngeal carcinoma


Description:

This trial was a single-arm, multicenter phase Ⅱ clinical study. Eligible oligometastatic NPC patients were scheduled to evaluate the efficacy and tolerance of local consolidative radiotherapy combined with camrelizumab and chemotherapy in patients with oligometastatic NPC. Progression-free survival (PFS) determined will be the primary outcome measures.


Recruitment information / eligibility

Status Recruiting
Enrollment 63
Est. completion date May 31, 2026
Est. primary completion date May 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - 1. 18-70 years old, no gender limit; - 2. Oligo metastasis is defined as less than or equal to 5 metastatic lesions and less than or equal to 2 metastatic organs - 3. Patients with an ECOG score of 0 or 1, and an expected survival period of =6 months; - 4. Has good organ function: 1. Hematology: WBC>3.0×109/L; ANC>1.5×109/L; Hb>90g/L; PLT>100×109/L; Albumin =3g/dL; 2. Liver function: bilirubin = 1.5 times the upper limit of normal (ULN) (patients with known Gilbert disease and serum bilirubin level = 3 times ULN can be included), AST and ALT = 3 times ULN (if liver metastases occur , Then AST/ALT=5 times ULN), and alkaline phosphatase=3 times ULN (if liver or bone metastasis occurs, ALP=5 times ULN); (3) Coagulation function: International normalized ratio (INR) or prothrombin time (PT) or activated partial thromboplastin time (APTT) = 1.5 times ULN; (4)Renal function: According to the Cockcroft-Gault formula (Appendix 8), serum creatinine =1.5 times ULN or creatinine clearance =60mL/min. - 5. Female subjects have a negative pregnancy test (for female patients with fertility); female patients without fertility; - 6. Male patients with fertility and female patients with fertility and risk of pregnancy must agree to take adequate contraceptive measures throughout the study period, and contraception lasts for 12 months after receiving this program. - 7. Patients who are willing and able to comply with visit arrangements, treatment plans, laboratory tests and other research procedures; - 8. During the research period, they are willing to comply with the arrangement and cannot participate in any other clinical research on drugs and medical devices; - 9. For patients who have previously received neoadjuvant chemotherapy, adjuvant chemotherapy, radiotherapy or radiotherapy for non-metastatic diseases, the time from the last chemotherapy and/or radiotherapy to randomization must reach a non-treatment interval of = 6 months . Oral S1 and capecitabine have no requirement for treatment interval for those who are progressing during chemotherapy. - 10. The patients sign a formal informed consent form to show that they understand that this study complies with the hospital's policies Exclusion Criteria: - 1. Those who have a history of severe immediate hypersensitivity to any of the drugs used in this study; - 2. Suffered from other malignant tumors other than nasopharyngeal carcinoma within 5 years (except for tumors with an expected 5-year OS>90%, such as non-melanoma skin cancer or pre-invasive cervical cancer); - 3. Any of the following conditions in the 6 months before screening: myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient cerebral ischemia Onset or symptomatic pulmonary embolism. Patients with known coronary artery disease, congestive heart failure that does not meet the above criteria, or left ventricular ejection fraction <50% must adopt an optimized and stable medical plan determined by the treating doctor. If appropriate, you can consult a cardiologist; - 4. Have received any of the following treatments: 1. Have received anti-PD-1 or anti-PD-L1 antibody therapy in the past; 2. Have received any investigational drug within 4 weeks before using the investigational drug for the first time; 3. A large number of glucocorticoids or other immunosuppressants (including but not limited to prednisone, dexamethasone, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor) have been used in the 4 weeks before treatment Subjects with anti-TNF drugs, or subjects in need of hormone therapy during clinical trials. Other special circumstances require communication with the sponsor. In the absence of active autoimmune diseases, inhaled or topical steroids and adrenal cortex hormones with a dose> 10 mg/day of prednisone are allowed to be substituted; 4. Those who have been vaccinated with anti-tumor vaccines or the study drug has been vaccinated with live vaccines within 4 weeks before the first administration; 5. Have undergone major surgery or severe trauma within 4 weeks before using the study drug for the first time; 6. Enroll in another clinical study at the same time, unless it is an observational (non-interventional) clinical study or an interventional clinical study follow-up; - 5. Patients with active autoimmune disease or a history of autoimmune disease but may relapse. Remarks: Patients with the following diseases are not excluded and can enter further screening: 1. Controlled type 1 diabetes 2. Hypothyroidism (if only hormone replacement therapy can be used to control) 3. Skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, hair loss) 4. Any other diseases that are not expected to recur without external triggers - 6. Active infections, including tuberculosis, hepatitis B, hepatitis C and human immunodeficiency virus. Patients with positive HBV surface antigen (HBsAg) but HBV DNA <1000 copies/mL are eligible to participate in this study; patients with positive HCV antibody test results are only allowed if the HCV RNA polymerase chain reaction test results are negative. Be selected for this study; - 7. Idiopathic pulmonary fibrosis, drug-induced pneumonia, organizing pneumonia (bronchiolitis obliterans), idiopathic pneumonia, or chest CT scan at the time of screening shows evidence of active pneumonia; - 8. Drug abuse or alcohol addiction; - 9. No capacity for civil conduct or limited capacity for civil conduct; - 10. The patient has a physical or mental illness, and the researcher believes that the patient cannot fully or fully understand the possible complications of this study; - 11. Other serious acute or chronic medical conditions (including immune colitis, inflammatory diseases, Enteropathy, non-infectious pneumonia, pulmonary fibrosis) or mental illness (including dementia and epilepsy, recent, past year or active suicidal ideation or behavior) or abnormal laboratory tests; - 12. Patients whose expected survival time is less than 6 months; - 13. Patients with significantly reduced heart, liver, lung, kidney and bone marrow functions - 14. Previously diagnosed as immunodeficiency or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related diseases; - 15. Female patients during pregnancy or lactation, male or female patients who are fertile but are unwilling or unable to use contraception during the entire study period and at least one year after the end of the treatment plan;

Study Design


Intervention

Radiation:
consolidative radiotherapy
local consolidative radiotherapy for all metastatic lesion (30-45Gy/3-8F)

Locations

Country Name City State
China Fujian Cancer Hospital Fuzhou Fujian
China Ganzhou Cancer Hospital Ganzhou Jiangxi
China Jiangxi Cancer Hospital Nanchang Jiangxi

Sponsors (1)

Lead Sponsor Collaborator
Jiangxi Provincial Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary progression-free survival The time from the start of treatment to the first observation of disease progression or death from any cause (whichever occurs first) 2 years
Secondary Objective response rate (ORR) the proportion of patients achieving the optimal overall remission (complete or partial remission) 2 years
Secondary Disease control rate (DCR) the proportion of patients with the best efficacy (CR or PR or SD) 2 years
Secondary Overall survival (OS) the time from the start of treatment to death from any cause 3 years
Secondary Duration of Overall Response (DOR) the time the patient first reaches complete or partial remission to disease progression 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06190782 - Local Therapy for Oligometastatic Esophageal Squamous Cell Cancer Patients Treated With PD-1 Inhibitor: a Prospective, Randomized, Phase III Clinical Trial. Phase 3
Recruiting NCT05377047 - Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer N/A
Recruiting NCT05223803 - TERPS Trial for de Novo Oligometastic Prostate Cancer Phase 2
Recruiting NCT04617457 - Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas Phase 2
Recruiting NCT04821765 - Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer Phase 2
Recruiting NCT05679427 - Ablative Radiosurgery vs Stereotactic RT in 5 Fractions With SIB for Oligometastatic Bone Lesions N/A
Recruiting NCT05277844 - Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC Phase 2
Active, not recruiting NCT05951127 - Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC N/A
Active, not recruiting NCT05101824 - Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease N/A
Recruiting NCT04748042 - Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) Phase 2
Not yet recruiting NCT06122480 - Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma Phase 2
Not yet recruiting NCT05784428 - Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression N/A
Recruiting NCT04593381 - Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer N/A
Terminated NCT01345539 - Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation Phase 2
Recruiting NCT05846646 - Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC Phase 2
Recruiting NCT04973007 - Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases Phase 4
Recruiting NCT05917431 - Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC Phase 2
Not yet recruiting NCT05903261 - Prospective Observational Basket Study of Stereotactic Body Radiation Therapy for OligoMetastatic Patients From Rare Tumors
Not yet recruiting NCT05375708 - Systemic Therapy in Combination With Stereotactic Radiotherapy in Patients With Metastatic Colorectal Cancer up to 10 Metastatic Sites Phase 2
Recruiting NCT05648370 - Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery